

Special Issue

Molecular Basis and Gene Therapies of Cystic Fibrosis

Message from the Guest Editors

The journal *Genes* is pleased to announce a Special Issue entitled “Molecular Basis and Gene Therapies of Cystic Fibrosis”, which is seeking original research contributions. Topics areas in this Special Issue will include three broad areas relevant to developing molecular therapies for cystic fibrosis (CF): 1) Molecular mechanisms of CFTR regulation.

- CFTR gene regulation
 - Post-transcriptional regulation of CFTR
 - CFTR regulation at the cellular level
 - Regulation of CFTR channel function
- 2) Disease pathogenesis
- Genotype/phenotype correlation
 - Molecular epidemiology of CF
 - Cellular models of CF disease processes
 - Cellular mechanisms of CF disease processes and CFTR function
 - Mechanisms of CF pathogenesis
 - Molecular diagnosis, genetic counseling, and penetrance of CFTR variants
- 3) Genetic therapies for cystic fibrosis.
- Gene editing
 - Gene replacement
 - Vector development
 - Testing of gene therapies in animal models

Guest Editors

Dr. John Engelhardt
Prof. Dr. Claude Ferec
Dr. Ziyang Yan

Deadline for manuscript submissions

closed (31 March 2020)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/33847

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))